U.S. Food and Drug Administration (FDA)
FDA Approves Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy
On November 21, 2016, the U.S. Food and Drug Administration approved daratumumab (Darzalex®, Janssen Biotech, Inc.) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
November 22, 2016